GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Buy GILD
up 109.93 %

Gilead Sciences, Inc. (GILD) rated Buy with price target $150 by Argus

Posted on: Tuesday,  Jun 23, 2015  1:25 PM ET by Argus

Argus rated Buy Gilead Sciences, Inc. (NASDAQ: GILD) on 06/23/2015. Previously Argus rated Buy Gilead Sciences, Inc. (NASDAQ: GILD) on 06/13/2013.,
when the stock price was $51.44. Since then, Gilead Sciences, Inc. has gained 109.93% as of 10/28/2015's recent price of $107.99.
If you would have followed the previous Argus's recommendation on GILD, you would have gained 109.93% of your investment in 867 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/23/2015 1:25 PM Buy
None
121.43 150.00
as of 8/27/2015
1 Week down  -5.63 %
1 Month down  -11.63 %
3 Months down  -0.68 %
1 YTD up  43.79 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2014 9:25 AM Buy
None
104.21 130.00
2/10/2014 8:25 AM Buy
None
78.99 90.00
11/1/2013 9:25 AM Buy
None
70.98 84.00
6/13/2013 8:25 AM Buy
None
51.44
11/23/2011 8:25 AM Hold
None
19.12

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy